

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application.

Listing of Claims:

1-75. (Cancelled)

76. (Currently amended) A method of ~~treating a patient in need thereof~~ decreasing clot formation, said method comprising administering to a patient in need thereof an effective amount of anticoagulant agent, and a protein C or activated protein C polypeptide with comprising a modified GLA domain and an anticoagulant agent, said modified GLA domain comprising the amino acid sequence of SEQ ID NO:1 with two, three, four, or five amino acid substitutions at positions selected from the group consisting of residues 10, 11, 28, 32, and 33 ~~of SEQ ID NO:1~~.

77. (Previously presented) The method of claim 76, wherein said anticoagulant agent is aspirin, warfarin, or heparin.

78. (Previously presented) The method of claim 77, wherein said anticoagulant agent is aspirin.

79. (Currently amended) ~~A method of treating a patient in need thereof, said method comprising administering an effective amount of protein C or activated protein C polypeptide with a modified GLA domain and an anticoagulant agent,~~ The method of claim 76, said modified GLA domain comprising the amino acid sequence of SEQ ID NO:1 with three amino acid substitutions at residues 11, 32, and 33 ~~of SEQ ID NO:1~~.

80. (Previously presented) The method of claim 79, wherein residue 32 of SEQ ID NO:1 is glutamic acid and residue 33 of SEQ ID NO:1 is aspartic acid.

81. (Previously presented) The method of claim 80, wherein residue 11 of SEQ ID NO:1 is glycine.

82. (Previously presented) The method of claim 80, wherein said anticoagulant agent is aspirin, warfarin, or heparin.

83. (Previously presented) The method of claim 81, wherein said anticoagulant agent is aspirin, warfarin, or heparin.

84. (Previously presented) The method of claim 82, wherein said anticoagulant agent is aspirin.

85. (Previously presented) The method of claim 83, wherein said anticoagulant agent is aspirin.

86. (Currently amended) ~~A method of treating a patient in need thereof, said method comprising administering an effective amount of activated protein C polypeptide with a modified GLA domain and aspirin,~~ The method of claim 76, said modified GLA domain comprising the amino acid sequence of SEQ ID NO:1 with three amino acid substitutions at residues 11, 32, and 33 of SEQ ID NO:1, wherein residue 11 of SEQ ID NO:1 is glycine, residue 32 of SEQ ID NO:1 is glutamic acid, and residue 33 of SEQ ID NO:1 is aspartic acid.